Our industry-leading SPR capabilities and advanced kinetic cell-binding assays enable precise analysis of binding interactions between recombinant proteins and cell-bound receptors. We perform comprehensive therapeutic-target interaction studies under physiologically relevant conditions, including dual-binding assays to assess binding dependency. Our kinetic cell-binding assays extend to membrane-bound receptors on live cells, providing critical insights into the dynamics of receptor-ligand engagement within their native cellular context. This dual approach ensures accurate characterisation of binding affinity and kinetics of interactions, whether in a purified system or within the complex environment of the cell membrane, and advances the understanding of your therapeutic’s molecular mechanism of action.

Our primary immune cell assays are designed to facilitate extended MOA characterisation, support the development of your in vitro pharmacology data package and identify biomarkers. We use a wide variety of human immune cells (e.g., T cells, NK cells, B cells) in our assays, designed to generate high-content data in a 96-well format. Key techniques include:

• Multi-parameter flow cytometry (up to 25 colours) using the Novocyte
• Multiplex cytokine analysis (up to 40 analytes) using Magpix Luminex or LegendPlex
• Kinetic assessments of cell viability or cytotoxicity using the xCELLigence RTCA 
• 3D cell assays with our partner ScreenIn3D

We also access primary patient material via our relationship with local biorepositories, validating mechanistic data from in vitro models providing insight into biomarkers for clinical study design.

For antibody-based drugs, our end-to-end characterisation solutions cover everything from target and Fcγ receptor binding to immune cell activation, signal transduction, and ultimately target cell death or phagocytosis. We offer assays for Fcγ and FcRn binding, C1q binding, ADCC, ADCP, CDC, and trogocytosis. Our bioanalytical experts deliver accurate and robust solutions that allow for fine resolution of effector function, using internally available target cell lines, engineered target cell lines, reporter, and primary effector cell populations, supported by:

• Direct access to recallable PBMC and whole blood donors (CD16a genotyped: V/V, V/F, F/F; CD32a genotyped: R/R, R/H, H/H; 4-digit HLA status known).
• Readily available cryopreserved PBMCs.
• Functional pre-screening assays for optimal donor selection.
• Isolated immune cells (stored banks or freshly prepared).

We tailor our immunotoxicology services to your specific needs by combining industry-standard approaches, cutting-edge technologies and advanced tools. Our customised assays align with regulatory expectations and our models address unique challenges, ensuring thorough safety evaluations to de-risk your path to the clinic. Our expert team navigates all complexities and delivers exceptional results in:

• Cytokine Release Assays/Infusion Related Reponses
• Unwanted immunogenicity (ADA assessments)
• Immunogenicity Hazard Assessments
• “On-target, Off-tumour” risk profiling